Intellia Therapeutics
开盘价
市值
最高价
最低价
收盘价
成交量
市盈率
股息率
Intellia Therapeutics简介
Intellia Treateutics，Inc.是一家临床阶段的基因组编辑公司，致力于使用CRISPR/Cas9系统开发治疗疗法。它的CRISPR/Cas9系统通过生产只需一个疗程就能永久编辑和/或纠正人体内疾病相关基因的疗法来改变医学，并创造出可以治疗肿瘤和免疫疾病的工程细胞。该公司由安德鲁·梅、卢西亚诺·马拉菲尼、鲁道夫·巴拉鲁、内森·伯明翰、雷切尔·豪尔维茨、埃里克·桑特海默、詹妮弗·杜德纳和德里克·罗西于2014年5月创立，总部位于马萨诸塞州剑桥市。
如何购买 Intellia Therapeutics (NTLA)
登录
1分钟开户
仅需1分钟即可完成账户申请和验证。整个过程完全自助，支持 RockFlow App 和网页端操作。
充值资金
账户验证完成后，您可以使用首选的支付方式向账户充值。
购买 NTLA
通过 RockFlow App 或网页端搜索 NTLA，输入您想要投资的金额，然后点击确认即可完成交易。
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.